Home » Extra Pulmonary Small Cell Carcinoma of Tongue

Extra Pulmonary Small Cell Carcinoma of Tongue

SUMMARY

Save Time On Research and Writing
Hire a Pro to Write You a 100% Plagiarism-Free Paper.
Get My Paper

We report a case of a 65-year-old previously healthy male diagnosed as extra pulmonary small cell carcinoma of tongue who presented initially with difficulty in swallowing and later, with a solitary neck lump. Unlike small cell carcinoma lung, extra pulmonary small cell carcinoma is uncommon and in base of tongue, it is extremely rare. The prognosis of extra pulmonary small cell carcinoma is felt to be extremely poor. Contrary to other reports, this case demonstrates that a good response with standard therapy is possible.

BACKGROUND

Extrapulmonary small cell carcinoma (EPSCC) was first described by Duguid and Kennedy in 1930, as a clinicopathological entity different from small cell carcinoma of the lung (SCLC).[1,2,3] The small cell carcinoma usually develops from the lung and only about 2.5-4% of it arises in extra pulmonary sites.[4,5] However, EPSCC is still often confused with metastatic SCLC.[6] Unlike SCLC, the natural history of EPSCC remains undiscovered and hence, optimal therapy determination is complicated.[7] The most commonly reported sites with EPSCC are aero-digestive tract including paranasal sinuses, nasal cavity, salivary glands, thyroid gland, larynx and trachea.[8] It has also been found rarely in ovaries, prostate gland, urinary bladder, cervix and breast.[9] In the head and neck region, oral cavity and oropharynx are the rarest sites for EPSCC. The EPSCC shares the similar histopathological features as of SCLC. The clinical course of EPSCC is more aggressive than SCLC and being more recurrent, it usually demonstrates a poorer prognosis.[6,7] The treatment of EPSCC patients has been very likely to the protocols used for treating SCLC. Due of its chemosensitive nature, most of the EPSCC patients have been treated with Cis-platinum based chemotherapy.[10] As it is a systemic disease, localized treatment as a sole modality produces only limited survival; so, multimodality therapy is preferred even at early stage.[10] Present case is a primary extrapulmonary small cell carcinoma with nodal metastasis in ipsilateral upper cervical node without paraneoplastic feature and good response to treatment suggesting a different clinicopathophysiological behaviour than typical pulmonary small cell carcinoma.

CASE PRESENTATION

Save Time On Research and Writing
Hire a Pro to Write You a 100% Plagiarism-Free Paper.
Get My Paper

A 65 years old male with 30 pack year history of smoking presented to radiotherapy department with difficulty in swallowing for the past 3 months. Initially the patient reported difficulty in swallowing to solid food which later progressed to semisolid food and eventually patient got dependent upon liquid diet only. The patient also reported associated history of pain in head and neck region since the past 2 months, which was continuous, progressive and relieved only after medication. The patient also reported lump in left side of the upper neck which was gradually progressive in nature and was associated with pain. There were no other risk factors such as any history of chewing tobacco or betel nuts. The patient was non-alcoholic. There was no significant past history related to hypertension, diabetes mellitus, tuberculosis or any other chronic illness. The rest of systemic review was unremarkable. The patient’s family history was not significant. Examination of the oral cavity revealed a large growth at the base of tongue associated with left sided upper deep cervical lymphadenopathy of neck level II, 3.5×2 cm firm, mobile mass was palpable. The rest of the systemic examination was unremarkable.

INVESTIGATIONS

Routine blood biochemistry parameters were within normal limits. The fiber optic endoscopy by the ENT specialist showed a large proliferative growth arising from left base of the tongue, involving the vallecula, left sided tonsil, while both of the vocal cords were normal and mobile. The fine needle aspiration cytology of the left sided neck node revealed small rounded cells with scant cytoplasm that demonstrated nuclear molding. However, since primary small cell carcinoma of the tongue is rare, a recommendation for biopsy of the tongue lesion was made for correlation and definitive diagnosis. The biopsy from the base of tongue lesion was consistent with small cell cancer (figure 1a and 1b). The immunohistochemical staining was positive for CK, synaptophysin and chromogranin A, and was negative for LCA and p63 (figure 2a, 2b and 2c). Hence a diagnosis of primary small cell carcinoma of the tongue with neck lymph node metastasis was confirmed. The pretreatment CECT scan revealed an ill defined heterogenous enhancing lesion with area of necrosis seen involving left hyoglossus muscle and left myelohyoid muscle alongwith involvement of left mesenteric space. Genioglossus muscle and left submandibular gland also appear to be involving. There is involvement of left vallecula and lesion is extending into subcutaneous fat on left side of neck (figure 3). CECT scan revealed multiple enlarged necrotic lymph nodes in bilateral jugular group and posterior triangle with largest of size 3.7cm x 1.8cm (figure 4). A large 3 cm lymph node was visualized posterior to the left internal jugular vein. No additional lymph node was seen. On PET/CT scan, neither parenchymal lung lesion nor mediastinal lymphadenopathy was noted, suggesting non pulmonary origin of the tumor. Blood profiling, ECG and liver and kidney functions test carried out for any suspected paraneoplastic finding but all parameters were within normal limits suggesting no paraneoplastic association in this case.

DIFFERENTIAL DIAGNOSIS

Small cell carcinoma is poorly differentiated neuroendocrine carcinoma. It must be distinguished from basaloid squamous cell carcinoma, solid variant of adenoid cystic carcinoma, mucosal malignant melanoma and merkel cell carcinoma. Presence of overlying squamous dysplasia is strongly supportive of the basaloid variant of squamous cell carcinoma. Immunohistochemistry is of limited value in its distinction from small cell carcinoma.[11]Malignant melanoma is strongly positive for HMB-45 and S-100 protein.

TREATMENT

The case was discussed in detail with a team comprising radiation oncologist, surgical oncologist, medical oncologist, as well as specialists in field of lung and head and neck cancer management, and it was decided to treat this as a case of extra pulmonary small cell lung carcinoma primarily arising from the base of the tongue. The tumor was staged as locally advanced (T4a N2a M0) stage disease, and it was recommended to treat him with neoadjuvant chemotherapy with injection cisplatin and etoposide intravenously, then followed by concomitant chemotherapy and radiation. Due to aggressive nature of extra pulmonary small cell carcinoma, it was decided to treat him with Cisplatin (75 mg/m2) and Etoposide (100 mg/m2) every twenty one days concomitant with radiation therapy. The patient completed 3 cycles of neoadjuvant chemotherapy and subsequently received 2 cycles of concomitant chemotherapy and total 64 Gy by bilateral parallel opposed field on telecobalt machine.

OUTCOME AND FOLLOW-UP

During treatment patient developed severe grade 3 mucositis and required parenteral nutrition and symptomatic treatment. The follow up PET/CT scan after 6 months treatment shows complete resolution of the tongue and neck mass and there was minimal post radiation uptake.

DISCUSSION

Small cell carcinoma usually develops from the lung and represents ~20–25% of all bronchogenic carcinomas.[12] Only about 2.5-4% of small cell carcinoma arises in extra pulmonary sites as EPSCC.[4,5] EPSCC represents an overall incidence of between 0.1% and 0.4% of all cancer.[13] However, EPSCC is still often confused with metastatic SCLC.[6] EPSCC found most commonly in aero-digestive tract including paranasal sinuses, nasal cavity, salivary glands, thyroid gland, larynx and trachea and rarely in ovaries, prostate gland, urinary bladder, cervix and breast.[8,9] For oropharyngeal carcinoma, the most common histopathology seen is squamous cell carcinoma, although other histologies like sarcoma, lymphoma etc are very rarely seen.[14] Only 0.2 to 1.6% of all tongue cancers are metastatic deposits.[6,15] In head and neck region, larynx is most common site followed by salivary glands, oral cavity and oropharynx are the rarest sites for EPSCC. EPSCC affects patients of middle age.[12] It is more common in male and in smokers.[4,8] Some of the previous studies have demonstrated that smoking is associated positively with EPSCC of particular sites particularly the head and neck or esophagus.[7] Present case also shows a tendency for this correlation.

SCLC is a very rapidly growing tumor with potential of distant metastasis even early in the course of the disease. It usually gets metastasized to bones, lymph nodes, adrenal gland, liver, oral cavity, tongue, gingival, parotid gland and brain.[15] EPSCC is a separate and very rare clinicopathological entity, but its clinical course is aggressive like SCLC, with early dissemination, and being recurrent in nature, it carries a poor prognosis.[,16] The patient in this study revealed no respiratory symptoms and short duration history of primary tongue mass and neck mass. Aggressive nature of the disease is revealed by the neck lymphadenopathy at the time of the diagnosis.

The EPSCC shares the similar histopathological features as of SCLC.[10] The pathological biopsy demonstrated cells with hyperchromatic nuclei, scanty cytoplasm, inconspicuous nucleoli, and a fragment showing showing fibrocollagenous tissue revealing infiltration by malignant small round cells. The immunohistochemistry showed focal positivity for CK which is consistent with small cell carcinoma. The immunohistochemistry for melanoma, primary breast, colon, lung and lymphoma were negative. The tumor cells were positive for neuroendocrine markers such as synaptophysin and chromogranin A on immunohistochemistry, similar to reported by Kim and Latif et al for small cell cancer.[8,9,17] The treatment of EPSCC patients has been very likely to the protocols used for treating SCLC. Multimodality therapy is preferred even at an early stage.[8,9,18] The patients are divided into 2 groups, limited or extensive disease. Limited disease (LD) is defined as a localized tumor with or without regional lymph node involvement that is easily encompassed within a radiation field. Any extension beyond the locoregional boundaries was defined as extensive disease (ED).[2,8] Multimodality therapy including chemotherapy in combination with radical surgery or radiotherapy is needed for patients with LD. The chemotherapeutic combinations used for treating EPSCC are similar to those of SCLC.[8] The most common regimens used is the combination of etoposide-cisplatinum or camptothecin- cisplatinum. The combination of etoposide and cisplatin (EP) is one of the most frequently used regimens, with a response rate of 69% in one study.[12] Median overall survival(OS) is 9.6 months for LD EPSCC disease and 9.2 months for ED EPSCC disease.[12] For EPSCC patients with ED, palliative therapy is given essentially. Cure is certainly possible in LD, and aggressive therapy is recommended. Complete resection is rarely achieved in EPSCC. Chemoradiation should be the primary form of management in EPSCC patients with LD. The chemotherapy regimen should contain a platinum compound.. RT should cover all known sites of primary tumor and involved lymph nodes to a dose equivalent of at least 50 Gy in 2 Gy fractions[19]. In the present case, the patient was treated with Cisplatin and Etoposide chemotherapy in neoadjuvant with three weekly cisplatin based concomitant radiation to the tongue base and ispilateral neck with excellent response to treatment and patient is disease free after six months of treatment

LEARNING POINTS/TAKE HOME MESSAGES

  • Oropharanx (Base of tongue) can be one of the rare site for extrapulmonary small cell carcinoma.
  • EPSCC is treated on the same protocols as for SCLC but no clear recommendations are there because of paucity of cases and very few studies.
  • Contrary to literature pertaining to extrapulmonary small cell carcinoma, good response with standard therapy is possible with meticulous treatment planning and multimodality interdisciplinary care.

REFERENCES

  1. Duguid JB, Kennedy AM. Oat-cell tumors of mediastinal glands. J Pathol Bacteriol 1930;33:93-9.
  2. Richardson RL, Weiland LH. Undifferentiated small cell carcinoma in extrapulmonary sites. Semin Oncol 1982;9:484-96.
  3. Galanis E, Frytak S, Lloyd RV. Extrapulmonary small cell carcinoma. Cancer 1997;79:1729-36.
  4. Ledermann JA. Extrapulmonary small cell carcinoma. Postgrad Med 1992;68:79-81.
  5. Terashima T, Matsuzaki T, Kawada I, Nishida J, Tanaka Y, et al. Tongue metastasis as an initial presentation of a lung cancer. Intern Med 2004;43:727-30.
  6. Remick SC, Hafez GR, Carbone PP. Extrapulmonary small-cell carcinoma. A review of the literature with emphasis on therapy and outcome. Medicine (Baltimore) 1987;66:457-71.
  7. Henricus FM, Yvonne F. Extrapulmonary small cell carcinoma. South Med J 2005;98:345-9.
  8. Kim KO, Lee HY, Chun SH, Shin SJ, Kim MK, et al. Clinical overview of extra pulmonary small cell carcinoma. J Korean Med Sci 2006;21:833-7.
  9. Latif N, Rosa M, Samian L, Rana F. An unusual case of primary small cell neuroendocrine carcinoma of the breast. Breast J 2010;16:647-51.
  10. Christodoulou C, Skarlos DV. Treatment of small cell lung cancer. Seminar Respir Crit Care Med 2005;26:333-41.
  11. Mills SE. Neuroectodermal Neoplasms of the Head and Neck with Emphasis on Neuroendocrine Carcinomas. Modern pathology 2002:15(3);264-78.
  12. Kim JH, Lee SH, Park J, Kim HY, Lee SI, Nam EM, et al. Extrapulmonary Small-cell Carcinoma: a Single-institution Experience. Jpn J Clin Oncol 2004;34(5):250–4.
  13. Haider K, Shahid RK, Finch D, Sami A, Ahmad I, Yadav S, et al. Extrapulmonary Small Cell Cancer : A Canadian Province’s Experience. Cancer 2006:107(9):2262-9.
  14. Licitra L, Bernier J, Grandi C, Merlano M, Bruzzi P, et al. Cancer of the oropharynx. Crit Rev Oncol Hematol 2002;41:107-22.
  15. Yildiz O, Buyuktas D, Ekiz E, Selcukbiricik F, Papila I, et al. Facial nerve palsy: an unusual presenting feature of small cell lung cancer. Case Rep Oncol 2011;4:35-8.
  16. Sengoz M, Abacioglu U, Salepci T, Ereb F, Yumuk F, Turhal S. Extrapulmonary small cell carcinoma: multimodality treatment results. Tumori 2003;89:274-7.
  17. Latif N, Imtiaz S, Wang B, Rana F, Wolfson D. Primary Small Cell Carcinoma of the Tongue. J Cancer Sci Ther 2012;5:7.
  18. N Jonas, J Fagan, H Wu, D Taylor.Neuroendocrine small cell carcinoma of the larynx. The Internet Journal of Otorhinolaryngology 2007;8:1.
  19. Brennan SM, Gregory DL, Stillie A, Herschtal A, Manus MM, Ball DL. Should Extrapulmonary Small Cell Cancer Be Managed Like Small Cell Lung Cancer? Cancer 2010:888-95.

FIGURE/VIDEO CAPTIONS

Figure 1a,1b- Overlying hyperplastic stratified squamous epithelium and underlying soft tissue revealing infiltration by inflammatory exudate and sheets of malignant small round cells (H&E 100x, 200x)

Figure 2a- Synaptophysin strongly positive in malignant small round cell (IHC 400x)

Figure 2b- Cytokeratin focally positive in tumor cells (IHC 200x)

Figure 2c- LCA negative in tumor cells(IHC 100 x)

Figure 3- Pretreatment CECT scan revealing an ill defined heterogenous enhancing lesion with area of necrosis involving left hyoglossus muscle, left myelohyoid muscle, genioglossus muscle and left submandibular gland. There is involvement of left vallecula and lesion is extending into subcutaneous fat on left side of neck.

Figure 4- CECT scan revealing multiple enlarged necrotic lymph nodes in bilateral jugular group and posterior triangle with largest of size 3.7cm x 1.8cm

PATIENT’S PERSPECTIVE

 

Copyright Statement

I, Dr Sumeet Aggarwal, The Corresponding Author, has the right to assign on behalf of all authors and does assign on behalf of all authors, a full assignment of all intellectual property rights for all content within the submitted case report (other than as agreed with the BMJ Publishing Group Ltd) (“BMJ”)) in any media known now or created in the future, and permits this case report (if accepted) to be published on BMJ Case Reports and to be fully exploited within the remit of the assignment as set out in the assignment which has been read. http://casereports.bmj.com/site/misc/copyright.pdf.

Date:14-05-2015

 

Place your order
(550 words)

Approximate price: $22

Calculate the price of your order

550 words
We'll send you the first draft for approval by September 11, 2018 at 10:52 AM
Total price:
$26
The price is based on these factors:
Academic level
Number of pages
Urgency
Basic features
  • Free title page and bibliography
  • Unlimited revisions
  • Plagiarism-free guarantee
  • Money-back guarantee
  • 24/7 support
On-demand options
  • Writer’s samples
  • Part-by-part delivery
  • Overnight delivery
  • Copies of used sources
  • Expert Proofreading
Paper format
  • 275 words per page
  • 12 pt Arial/Times New Roman
  • Double line spacing
  • Any citation style (APA, MLA, Chicago/Turabian, Harvard)

Our guarantees

Delivering a high-quality product at a reasonable price is not enough anymore.
That’s why we have developed 5 beneficial guarantees that will make your experience with our service enjoyable, easy, and safe.

Money-back guarantee

You have to be 100% sure of the quality of your product to give a money-back guarantee. This describes us perfectly. Make sure that this guarantee is totally transparent.

Read more

Zero-plagiarism guarantee

Each paper is composed from scratch, according to your instructions. It is then checked by our plagiarism-detection software. There is no gap where plagiarism could squeeze in.

Read more

Free-revision policy

Thanks to our free revisions, there is no way for you to be unsatisfied. We will work on your paper until you are completely happy with the result.

Read more

Privacy policy

Your email is safe, as we store it according to international data protection rules. Your bank details are secure, as we use only reliable payment systems.

Read more

Fair-cooperation guarantee

By sending us your money, you buy the service we provide. Check out our terms and conditions if you prefer business talks to be laid out in official language.

Read more
Live Chat+1 763 309 4299EmailWhatsApp

We Can Handle your Online Class from as low as$100 per week